ArticleJournal of translational medicine2018
Screening and identification of a six-cytokine biosignature for detecting TB infection and discriminating active from latent TB.
Article in Journal of translational medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Diagnostic accuracy ofFrontiers in immunology · 2026Pooled it
- Vascular endothelial growth factor levels in tuberculosis: A systematic review and meta-analysis.PloS one · 2022Pooled it
- Is interleukin-2 an optimal marker for diagnosing tuberculosis infection? A systematic review and meta-analysis.Annals of medicine · 2020Pooled it
- Pooled it
- Multiplexed cytokine profiling identifies diagnostic signatures for latent tuberculosis and reactivation risk stratification.PloS one · 2025Article
- Multiple cytokine analysis based on QuantiFERON-TB gold plus in different tuberculosis infection status: an exploratory study.BMC infectious diseases · 2024Article
- Challenges and the Way forward in Diagnosis and Treatment of Tuberculosis Infection.Tropical medicine and infectious disease · 2023Review
- Plasma CXCL8 and MCP-1 as surrogate plasma biomarkers of latent tuberculosis infection among household contacts-A cross-sectional study.PLOS global public health · 2023Article
- Differential Frequencies of Intermediate Monocyte Subsets Among Individuals Infected With Drug-Sensitive or Drug-ResistantFrontiers in immunology · 2022Article
- Tuberculosis Phenotypic and Genotypic Drug Susceptibility Testing and Immunodiagnostics: A Review.Frontiers in immunology · 2022Review
- Article
- Review
- A systematic review of potential screening biomarkers for active TB disease.Journal of clinical tuberculosis and other mycobacterial diseases · 2021Review
- Cytokine Biosignature of Active and Latent Mycobacterium Tuberculosis Infection in Children.Pathogens (Basel, Switzerland) · 2021Article
- A Plasma 5-Marker Host Biosignature Identifies Tuberculosis in High and Low Endemic Countries.Frontiers in immunology · 2021Article
- Host and Bacterial Iron Homeostasis, an Underexplored Area in Tuberculosis Biomarker Research.Frontiers in immunology · 2021Review
- Differential Diagnosis of Latent Tuberculosis Infection and Active Tuberculosis: A Key to a Successful Tuberculosis Control Strategy.Frontiers in microbiology · 2021Review
- Antigen-Specific Cytokine and Chemokine Gene Expression for Diagnosing Latent and Active Tuberculosis.Diagnostics (Basel, Switzerland) · 2020Article
- Identification of candidate host serum and saliva biomarkers for a better diagnosis of active and latent tuberculosis infection.PloS one · 2020Article
- Cell-Mediated Immune Responses toFrontiers in immunology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe early and accurate diagnosis of tuberculosis (TB) is critical for controlling the global TB epidemic. Although early studies have supported the potential role of cytokine biomarkers in blood for the diagnosis of TB, this method requires further investigation and validation in different populations. A set of biomarkers that can discriminate between active TB (ATB) and latent TB infection (LTBI) remains elusive.
methodsIn the current study, we organized two retrospective cohorts and one prospective cohort to investigate the immune responses at different clinical stages of TB infection, as determined by candidate cytokine biomarkers detected with a multiplex cytokine platform. Using a pre-established diagnostic algorithm, participants were classified as ATB, LTBI, and TB uninfected controls (CON). Based on our multiplex cytokine assay, a multi-cytokine biosignature was modelled for the optimal recognition of the different TB infection status.
resultsOur analysis identified a six-cytokine biosignature of TB-antigen stimulated IFN-γ, IP-10, and IL-1Ra, and unstimulated IP-10, VEGF, and IL-12 (p70) for a biomarker screening group (n = 88). The diagnostic performance of the biosignature was then validated using a biomarker validation cohort (n = 216) and resulted in a sensitivity of 88.2% and a specificity of 92.1%. In a prospectively recruited clinical validation cohort (n = 194), the six-cytokine biosignature was further evaluated, and displayed a sensitivity of 85.7%, a specificity of 91.3% and an overall accuracy of 88.7%.
conclusionsWe have identified a six-cytokine biosignature for accurately differentiating ATB patients from subjects with LTBI and CON. This approach holds promise as an early and rapid diagnostic test for ATB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.